Skip to main content
. 2018 Aug 17;9(3):287–297. doi: 10.1007/s13167-018-0147-5

Fig. 5.

Fig. 5

Amounts of LysoPC(16:0) and LysoPC(20:4(5Z,8Z,11Z,14Z)) in the serum of PC and BTC patients. The amounts of the two metabolites (unit:logarithm of the mass peak area) were slightly lower in the PC, BTC, CRC and OVC groups than in the control group, and no single metabolite could discriminate between the cancer groups and the control group